Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Why 2017 Was a Year to Forget for Pfizer Inc.
Why 2017 Was a Year to Forget for Pfizer Inc.
The S&P 500 index soared 19% in 2017 (so far). The healthcare sector performed even better, with year-to-date gains of close to 21%. Several major drugmakers completed significant....
AbbVie Makes Progress on Quest to Diversify
AbbVie Makes Progress on Quest to Diversify
AbbVie's (NYSE: ABBV) Humira will face-off against cheaper biosimilars in the coming years, and that's bad news because Humira generates about two-thirds of AbbVie's companywide....
3 Dividend Stocks to Buy on Sale
3 Dividend Stocks to Buy on Sale
Stocks that pay out the highest dividend yields aren't always the best ones to buy. Sometimes, the yields are artificially high in advance of a big dividend cut. And sometimes the dividend is....
You'll Be Stunned by How Many Cancer Immunotherapies Are Being Developed
You'll Be Stunned by How Many Cancer Immunotherapies Are Being Developed
For years, chemotherapy was the best treatment that the world of medicine had to offer in fighting cancer. That's no longer true. A powerful new class of cancer drugs called immunotherapies has....
Is Gilead Sciences, Inc. a Buy?
Is Gilead Sciences, Inc. a Buy?
With only a few weeks remaining in 2017, Gilead Sciences (NASDAQ: GILD) stock price appears to be on course to finish roughly at the same level that it began the year. After getting off to a rocky....
3 Growth Stocks I'd Buy Right Now
3 Growth Stocks I'd Buy Right Now
What's a six-letter word that's guaranteed to make investors happy? Growth. While growth comes in several flavors, they're all interrelated. Growth in revenue helps make earnings growth possible,....
Better Buy: Pfizer (PFE) vs. AbbVie (ABBV)
Better Buy: Pfizer (PFE) vs. AbbVie (ABBV)
For Pfizer (NYSE: PFE), 2017 so far has looked better than the past couple of years in terms of stock performance. However, the stock's 9% year-to-date gain isn't anything to jump up and down....
Will Johnson & Johnson Raise Its Dividend in 2018?
Will Johnson & Johnson Raise Its Dividend in 2018?
Just about everyone has some products from Johnson & Johnson (NYSE: JNJ) in their medicine cabinets, ranging from over-the-counter medicines like Tylenol and Benadryl to Band-Aid bandages. Yet....
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Better luck next year. That's what Merck & Co. (NYSE: MRK) is hoping for after a disappointing 2017. Merck stock is down year to date by 7%, while the S&P 500 index is up close to 18%.Will....
2 Top Consumer Staples Stocks to Consider Buying Now -- and 1 to Avoid
2 Top Consumer Staples Stocks to Consider Buying Now -- and 1 to Avoid
Recessions are common enough that you can count on several of them impacting your portfolio over the course of even a 10-year time horizon. That's just one reason why consumer staples stocks --....
This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November
This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biopharmaceutical company that develops treatments for eye disorders and other serious medical conditions, tumbled 10% during the....
Why Alexion Pharmacteuicals Sank 8.9% in November
Why Alexion Pharmacteuicals Sank 8.9% in November
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a commercial-stage biotech focused on rare diseases, fell 9% in November, according to data from S&P Global Market Intelligence. There doesn't....
Will 2018 Be Johnson & Johnson's Best Year Yet?
Will 2018 Be Johnson & Johnson's Best Year Yet?
There are still several weeks left in the year, but Johnson & Johnson (NYSE: JNJ) appears to be on course to generate its second-highest stock performance over the last decade in 2017. A....
5 Top Biotech Stocks to Buy Now
5 Top Biotech Stocks to Buy Now
Over the last five years, biotech stocks have trounced the performance of the S&P 500. One major reason why is the number of new drugs launched by biotech companies. More diseases than ever....
Better Buy: Pfizer Inc. vs. Johnson & Johnson
Better Buy: Pfizer Inc. vs. Johnson & Johnson
With only one month remaining in 2017, it's pretty clear which big pharma stock has been the better pick this year between Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ). J&J's share....
Gilead Sciences Stock Upgraded: This Is the Power of Free
Gilead Sciences Stock Upgraded: This Is the Power of Free
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....
Will Johnson & Johnson Do a Stock Split in 2018?
Will Johnson & Johnson Do a Stock Split in 2018?
Healthcare has been an exciting industry lately, and Johnson & Johnson (NYSE: JNJ) casts a wide net over the sector. The company not only sells well-known consumer brands like Tylenol and....
Healthcare Investing Risks and How to Mitigate Them
Healthcare Investing Risks and How to Mitigate Them
Healthcare is constantly coming under the fire of political and media attention, and biotech companies are going boom or bust on FDA approvals that are out of their control. But healthcare is also....
3 Top Big Pharma Stocks to Buy Now
3 Top Big Pharma Stocks to Buy Now
Big pharma stocks have been longtime favorites among investors for several reasons. The fact that they're big means that that they generate huge cash flow, which typically translates to attractive....
3 Dividend Stocks With Better Yields Than McDonald's
3 Dividend Stocks With Better Yields Than McDonald's
If you want fast food, McDonald's Corporation (NYSE: MCD) might be a good option. But despite the stock's status as a Dividend Aristocrat, there are better alternatives than McDonald's if you're....
Biogen Inc. Buys Its Way Out of Competition
Biogen Inc. Buys Its Way Out of Competition
Biogen (NASDAQ: BIIB) is following the old saying, "If you can't beat 'em, join 'em" for its multibillion drug Tecfidera or, more accurately, "If you might not be able to beat 'em later, license....
Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.
Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.
These big pharma stocks have something for everyone. Income investors love the dividends Eli Lilly and Co. (NYSE: LLY) and Merck & Co., Inc. (NYSE: MRK) pay each quarter, while dreams of....
3 Top Diabetes Stocks to Buy Now
3 Top Diabetes Stocks to Buy Now
Diabetes is huge problem for Americans. Between 1990 and 2010, the number of U.S. residents with diabetes tripled, and the number of new cases annually doubled. Both prevalence and costs....
5 Cancer Types With the Poorest Long-Term Outlook
5 Cancer Types With the Poorest Long-Term Outlook
There's arguably no scarier diagnosis a patient can receive from their doctor than cancer. But the grim reality, based on data from the National Cancer Institute's Surveillance, Epidemiology, and....
How to Diversify Your Healthcare Investments
How to Diversify Your Healthcare Investments
On this week's episode of Industry Focus: Healthcare, analysts Kristine Harjes and Todd Campbell get back to basics and explain what you need to know about diversifying your portfolio, especially....